Genome-wide association study identifies new locus associated with OCD

Competing Interest Statement

Ole Andreassen is a consultant to HealthLytix and has received speakers honorarium from Lundbeck and Sunovion in the past. CM Bulik reports: Shire (grant recipient, Scientific Advisory Board member); Idorsia (consultant); Lundbeckfonden (grant recipient); Pearson (author, royalty recipient). David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health, and personal fees for editorial work from Elsevier, all unrelated to the current work. Hans-Joerg Grabe has received travel grants and speakers honoraria from Fresenius Medical Care, Neuraxpharm, Servier and Janssen Cilag, as well as research funding from Fresenius Medical Care. Jan Haavik has received lecture honoraria as part of continuing medical education programs sponsored by Shire, Takeda and Medice. Professor Ian Hickie was an inaugural Commissioner on Australia's National Mental Health Commission (2012-18). He is the Co-Director, Health and Policy at the Brain and Mind Centre (BMC) University of Sydney, Australia. The BMC operates an early-intervention youth services at Camperdown under contract to headspace. Professor Hickie has previously led community-based and pharmaceutical industry-supported (Wyeth, Eli Lily, Servier, Pfizer, AstraZeneca) projects focused on the identification and better management of anxiety and depression. He was a member of the Medical Advisory Panel for Medibank Private until October 2017, a Board Member of Psychosis Australia Trust and a member of Veterans Mental Health Clinical Reference group. He is the Chief Scientific Advisor to, and a 5% equity shareholder in, InnoWell Pty Ltd. InnoWell was formed by the University of Sydney (45% equity) and PwC (Australia; 45% equity) to deliver the $30 M Australian Government-funded Project Synergy (2017-20; a three-year program for the transformation of mental health services) and to lead transformation of mental health services internationally through the use of innovative technologies. Erika Nurmi is member of the Scientific Advisory Board for Myriad Genetics and the Medical Advisory Board for Teva Pharmaceuticals and the Tourette Association of America.

Funding Statement

A.A. and KJHV were supported by the Foundation Volksbond Rotterdam. MoBa is supported by the Norwegian Ministry of Health and Care Services and the Ministry of Education and Research. We are grateful to all the participating families in Norway who take part in this ongoing cohort study. We thank the Norwegian Institute of Public Health for generating high-quality genomic data. This research is part of the HARVEST collaboration, supported by the Research Council of Norway (RCN) (229624). We also thank the NORMENT Centre for providing genotype data, funded by the RCN (223273), South East Norway Health Authority (SENHA) and KG Jebsen Stiftelsen. We further thank the Center for Diabetes Research, the University of Bergen for providing genotype data and performing quality control and imputation of the data funded by the ERC AdG project SELECTionPRE-DISPOSED, Stiftelsen Kristian Gerhard Jebsen, Trond Mohn Foundation, the NRC, the Novo Nordisk Foundation, the University of Bergen, and the Western Norway health Authorities. The Anorexia Nervosa Genetics Initiative (ANGI), an initiative of the Klarman Family Foundation. JK has been supported by the Academy of Finland (grant 336823). This study is funded by "Gentransmed" Centre of Excellence, ERDF nr 2014-2020.4.01.15-0012. MSA is a recipient of a Juan de la Cierva Incorporacion contract (IJC2018-035346-I) from the Ministry of Science, Innovation and Universities, Spain. This investigation was supported by Instituto de Salud Carlos III (PI19/00721, P19/01224 and PI20/00041), and cofinanced by the European Regional Development Fund (ERDF), "la Marato de TV3" (092330/31), the Agencia de Gestio d'Ajuts Universitaris i de Recerca-AGAUR, Generalitat de Catalunya (2014SGR1357 and 2017SGR1461) and the Pla estrategic de recerca i innovacio en salut (PERIS), Generalitat de Catalunya (MENTAL-Cat; SLT006/17/287). This project has also received funding from the European Union's Horizon 2020 Research and Innovation Programme under the grant agreements No 667302 (CoCA) and 728018 (Eat2beNICE). J.A.R.Q was on the speakers' bureau and/or acted as consultant for Janssen-Cilag, Novartis, Shire, Takeda, Bial, Shionogi, Sincrolab, Novartis, BMS, Medice, Rubio, Uriach and Raffo in the last 3 years. He also received travel awards (air tickets + hotel) for taking part in psychiatric meetings from Janssen-Cilag, Rubio, Shire, Takeda, Shionogi, Bial and Medice. The Department of Psychiatry chaired by him received unrestricted educational and research support from the following companies in the last 3 years: Janssen-Cilag, Shire, Oryzon, Roche, Psious, and Rubio. Some of the data were collected as part of the following NIH grant: 1R01MH09338. The EPOC study was funded by the German Research Foundation, grants RA1971/8-1, WA731/10-1, WA731/15-1, and KA815/6-1. The GENOS study was supported by the German Research Foundation (GR 1912/1-1). The research at EstBB was supported by the European Union through the European Regional Development Fund (Project No. 2014-2020.4.01.16-0125), the Estonian Research Council grant PUT (PRG184), and through the CoMorMent project. CoMorMent has received funding from the European Union's Horizon 2020 Research and Innovation Programme under Grant agreement 847776. SEM is supported by an Australian NHMRC Investigator Grant (APP1172917). The AGDS was primarily funded by National Health and Medical Research Council (NHMRC) of Australia grant 1086683. This work was further supported by NHMRC grants 1145645, 1078901 and 1087889. LCC is supported by a QIMR Berghofer Institute fellowship. NORDiC is funded by NIMH R01 MH110427 (PI Crowley), NIMH R01 MH105500 (PI Crowley) and the Swedish Research Council grant 2015-02271 (PI Mataix-Cols). Funding support for some of the Swedish controls was provided by the Klarman Family Foundation, the Swedish Research Council (Vetenskapsradet, award: 538-2013-8864, and the NIMH Center for Collaborative Genomics Research on Mental Disorders (award U24 MH068457). This study was also supported by NIMH R01MH085321, NIMH R01MH101493, NIMH R01MH58376, and NIMH K20MH01065. It was furthermore funded by NIH R21 MH109938. Support was also provided by the German Research Foundation through grant KA815/6. The Research Council of Norway supported H. Ask, and T. Reichborn-Kjennerud (27611). A. Havdahl was supported by South East Norway Health Authority (2020022). Grant support was also provided from RCN (273291, 262656, 248778, 223273) and the KG Jebsen Stiftelsen. LifeGene was supported by grants from the Ragnar and Torsten Soederberg Foundation, AFA Insurance, the Swedish Research Council and Karolinska Institutet. It is currently a core facility at Karolinska Institutet. The Trondelag Health Study (The HUNT Study) is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology), Trondelag County Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public Health. The genotyping was financed by the National Institute of health (NIH), University of Michigan, The Norwegian Research council, and Central Norway Regional Health Authority and the Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU). The genotype quality control and imputation has been conducted by the K.G. Jebsen center for genetic epidemiology, Department of public health and nursing, Faculty of medicine and health sciences, Norwegian University of Science and Technology (NTNU). EGOS was supported by a grant from the Beatrice and Samual A. Seaver Foundation to DEG. The OCD Collaborative Genetics Association Study (OCGAS) is a collaborative research study and was funded by the following NIMH Grant Numbers: MH071507 (G N), MH079489 (DAG), MH079487 (JM), MH079488 (AF), and MH079494 (JK). Yao Shugart and Wei Guo were also supported by the Intramural Research Program of the NIMH (MH002930-06). The International Obsessive Compulsive Foundation Genetics Collaborative (IOCDF-GC) was supported by a grant from the David Judah Foundation (a private, non-industry related foundation established by a family affected by OCD), MH079489 (DLP), MH073250 (DLP), S40024 (JMS), MH 085057 (JMS), and MH087748 (CAM).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Individual studies obtained approvals from their local IRB / oversight body: The OCGAS study (comprising of OCGAS_all, OCGAS_Nestadt, OCGAS_ab, and OCGAS_gh) was approved by the Hopkins Medicine Institutional Review Boards, the Butler Institutional Review Board, the UCLA Institutional Review Boards, the Mass General Brigham Human Research Committee, the Columbia University Institutional Review Boards, and the National Institutes of Health Institutional Review Board (NIH IRB). Furthermore the OCGAS_gh study was approved by the Ethic Committees from Aachen, Wuerzburg, Marburg, Freiburg and the Cantonal Ethic Commission of Zuerich (Ref. Nr. 39/97, 140/3 and EK: KEK-ZH-Nr. 2010-0340/3). The IOCDF-GC study (comprising of IOCDF-GC and 610k_trio) was approved by the relevant IRBs at all participating sites. This includes the local IRBs in Bonn, Germany, and Capetown, South Africa. Overall IRB was obtained from the the Mass General Brigham Human Research Committee (which includes the use of controls obtained through the dbGaP repository). The Spanish Mental-Cat clinical sample and the INSchool population-based cohort have been approved by the Clinical Research Ethics Committee (CREC) of Hospital Universitari Vall d'Hebron. For AGDS all study protocols were approved by the QIMR Berghofer Medical Research Institute Human Research Ethics Committee. The protocol for approaching participants through the DHS, enrolling them in the study, and consenting for all phases of the study (including invitation to future related studies) and accessing MBS and PBS records was approved by the Ethics Department of the Department of Human Services. The iPSYCH study was approved by the Regional Scientific Ethics Committee in Denmark and the Danish Data Protection Agency. The EPOC study was approved approved by the local ethics committees of the Charite University Medicine Berlin and the University Hospital Bonn. The Ethical Review Board of the Hospital District of Helsinki and Uusimaa approved the FinnGen study protocol Nr. HUS/990/2017. The FinnGen project was approved by Finnish Institute for Health and Welfare (THL), approval numbers THL/2031/6.02.00/2017, amend-ments THL/341/6.02.00/2018, THL/2222/6.02.00/2018 and THL/283/6.02.00/2019. The HUNT study was approved by the Regional Committee for Medical and Health Research Ethics, Norway (2015/575). The establishment of MoBa and initial data collection was based on a license from the Norwegian Data Protection Agency and approval from The Regional Committees for Medical and Health Research Ethics. The OCD-WWF study was approved by the ethics committee of the University of Wuerzburg, Germany. Ethical approvals for EGOS were obtained from the Institutional Review Board (IRB) at the Icahn School of Medicine at Mount Sinai, New York, NY, and the Regional Ethical Review Board in Stockholm. The NORDiC-SWE study was approved by the Regional Ethics Committee, Stockholm (EPN Stockholm) and the Institutional Review Board (IRB) at the University of North Carolina at Chapel Hill. The NORDiC-NOR study was approved by the Norwegian Regional Committee for Medical and Health Research Ethics (REC-West) under project number 2018/52 REKVest (PI Bjarne Hansen) and project number: 2014/75 REKVest (PI: Jan Haavik). The Vanderbilt University Medical Center Institutional Review Board oversees BioVU and approved this project (IRB201609). Individual level data analysis in the EstBB was carried out under ethical approval from the Estonian Committee on Bioethics and Human Research (Estonian Ministry of Social Affairs) and data release N05 from the EstBB. This research was approved to be conducted under that approval by the governing Research Ethics Committee of the UK Biobank. The analyses in this paper were performed under an approved extension to project 16577.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes